Advanced Filters
noise

Alcobendas, Spain Clinical Trials

A listing of Alcobendas, Spain clinical trials actively recruiting patients volunteers.

Found 1,211 clinical trials

First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System

The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device. The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent. The …

60 years of age All Phase N/A

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the …

18 years of age All Phase 1
L Luis Miguel Sáez-Alcaide, PhD Student

"Pontic-shield" Technique in Alveolar Ridge Preservation

Alveolar bone resorption after dental extraction frequently leads to situations in which long-term function and esthetic success of rehabilitations with dental implants is a challenge. "Pontic-shield" has been described as an alternative technique to maintain alveolar ridge after tooth extraction. The aim of this study is to analyze the effectiveness …

18 - 80 years of age All Phase N/A

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B …

- 18 years of age All Phase 1
C Conchita Martin, Prof

Effect of MOPs During Orthodontic Movement in Periodontitis Patients

Micro-osteoperforations (MOPs) cause cortical bone injuries and consequently increase the expression of inflammatory mediators, allowing for increased bone and periodontal ligament remodeling associated with orthodontic movement. It remains unclear the effect of orthodontic intrusion combined with MOPs application on teeth with reduced periodontium. The general objective will be to determine …

18 - 80 years of age All Phase N/A

PM534 Administered Intravenously to Patients With Advanced Solid Tumors

The goals of this trial are to identify the dose limiting toxicities, to determine the maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid tumors. All Patients will receive PM534 via intravenous.

18 years of age All Phase 1

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

Lung cancer (LC) is the tumor responsible for the highest mortality worldwide. Lung adenocarcinoma is the major subtype of lung cancer and represents the deadliest human cancer, affecting current-, ex-, and even non-smokers. Osimertinib is indicated as monotherapy for the first-line (1L) treatment of adult patients with locally advanced or …

18 years of age All Phase N/A
A Ana Fernández Cruz, MDPhD

Usefulness of PET-CT for Invasive Fungal Infection

The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management. The main questions it aims to answer are: Does the use of 18F-FDG PET-CT allow a better characterization of invasive fungal infection (IFI) (performance) compared …

18 years of age All Phase N/A
A Antonio Avallone, MD

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

This is a proof-of-concept, Open label, randomized, multicentric, superiority phase-2 study.

18 years of age All Phase 2

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Multicenter, prospective, non-controlled study in a pediatric cohort (\<6 years-old) with severe (type 2 or 3) hereditary Von Willebrand Disease (VWD).

2 - 6 years of age All Phase 4

Simplify language using AI